Amarin: 3 Key Takeaways for Long-Term Investors

Amarin (AMRN -0.34%) achieved profitability in its third quarter of 2026 after undergoing a corporate restructuring and cutting operating expenses by nearly half. The company reported $9 million in operating cash flow through international distribution partnerships in Europe and generated $245,000 in net income, despite competition from U.S. generic drug makers.

The company's commercial partner Recordati expanded distribution of its prescription cardiovascular drug VAZKEPA in Europe, driving a 68% increase in market demand year over year. Amarin outsources overseas sales to enter multiple international markets without investing in local commercial teams.

In a phase III trial, Amarin's omega-3 heart medication VASCEPA showed a 32% lower hazard of death in patients undergoing surgery for colorectal cancer liver metastases, compared to overall survival rates. Although the trial fell short of its primary endpoint measuring progression-free survival, the statistically significant finding is meaningful for patients with a high risk of recurrence within two years following surgery.

Amarin has reported four consecutive quarters of positive cash flow and zero debt, providing the company with stability as global demand for its products expands. The company's partnerships with international distributors and patent protection through 2039 offer operational advantages. Management is monitoring pricing discipline to ensure long-term shareholder value.

The company is currently evaluating options for capital deployment with financial advisor Barclays, including share repurchases. Amarin's leadership believes the company is in a stronger position to deliver value to shareholders than at any point in its recent history. The Motley Fool's Stock Advisor recommends the company as one of the 10 best stocks for investors to buy right now, based on its total average return of 835% compared to the S&P 500's 208%.